José Juan
García Marín
Catedrático de Universidad
Hospital Universitario de Donostia
San Sebastián, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Donostia (33)
2022
-
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
Hepatology, Vol. 76, Núm. 5, pp. 1259-1274
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation
Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004
2021
-
Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity
Cell Death and Disease, Vol. 12, Núm. 6
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma
Hepatology, Vol. 73, Núm. 6, pp. 2380-2396
-
Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis
Molecular Metabolism, Vol. 53
-
Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease
Hepatology, Vol. 73, Núm. 1, pp. 186-203
-
Targeted therapies for extrahepatic cholangiocarcinoma: preclinical and clinical development and prospects for the clinic
Expert Opinion on Investigational Drugs, Vol. 30, Núm. 4, pp. 377-388
2020
-
A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma
Cancers, Vol. 12, Núm. 6
-
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
-
Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis
Cancers, Vol. 12, Núm. 12, pp. 1-27
-
MRP3-Mediated Chemoresistance in Cholangiocarcinoma: Target for Chemosensitization Through Restoring SOX17 Expression
Hepatology, Vol. 72, Núm. 3, pp. 949-964
-
Multi‐omics integration highlights the role of ubiquitination in ccl4‐induced liver fibrosis
International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-19
-
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis
Cells, Vol. 9, Núm. 3
-
Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach
Cancers, Vol. 12, Núm. 6, pp. 1-30
2019
-
Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy
Hepatology, Vol. 70, Núm. 4, pp. 1246-1261
-
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
Hepatology, Vol. 70, Núm. 2, pp. 547-562
-
Wnt–β-catenin signalling in liver development, health and disease
Nature Reviews Gastroenterology and Hepatology, Vol. 16, Núm. 2, pp. 121-136